June 4, 2018

New guidelines for HER2 testing in breast cancer

An image of the HER2 protein.

Current HER2 tests help predict which breast cancer patients will respond to HER2-targeted therapies, but sometimes these tests provide unclear results. An Expert Panel of pathologists and cancer researchers, including Dr. John Bartlett from OICR, recently published revised clinical practice guidelines for HER2 testing in breast cancer to help improve clarity of HER2 test results.

Continue reading – New guidelines for HER2 testing in breast cancer

November 23, 2016

OICR and OMPRN celebrate International Pathology Day with educational events

A technician works in OICR pathology lab

On November 16 OICR and the Ontario Molecular Pathology Research Network (OMPRN) joined other organizations around the world celebrating International Pathology Day.

Continue reading – OICR and OMPRN celebrate International Pathology Day with educational events

November 4, 2016

Beyond the crime scene: You don’t have to be dead to need a pathologist

Cafe Scientifique banner

Dr. John Bartlett, from the Ontario Institute for Cancer Research, and Dr. Michelle Downes, from Sunnybrook Health Science Centre, will take you into a world of pathology beyond crime scene investigation and into puzzles more complex than an escape room. They will talk about the future of pathology and how this is changing the face of medicine and why a pathologist is considered ‘the doctor’s doctor’.

The Duke of York Pub – November 16, 6-8 p.m.
39 Prince Arthur Avenue, Toronto
near St. George subway station

Register at Eventbrite >

August 17, 2016

New retrospective study aims to identify mutations to better diagnose breast cancer in the future

Toronto (August 17, 2016) – Mr. Peter Goodhand, President of The Ontario Institute for Cancer Research (OICR), today announced a new collaborative research study in partnership with Thermo Fisher Scientific and Queen’s University to help bring more targeted diagnosis and treatment to breast cancer patients in the future.

Continue reading – New retrospective study aims to identify mutations to better diagnose breast cancer in the future

June 1, 2016

Making prostate cancer diagnosis more PRECISE

Dr. Laurence Klotz of the Sunnybrook Research Institute

Dr. Laurence Klotz of Sunnybrook Health Sciences Centre is a world leader in the field of prostate cancer research. He has been a champion of active surveillance (also known as watchful waiting) for over 20 years, an approach to prostate cancer treatment that has allowed thousands of men with low-risk prostate cancer to avoid or delay therapy by monitoring it closely instead of immediately treating it.

Now Klotz has launched a new clinical trial called PRECISE, funded with $3 million in support by the Movember Foundation, the Ontario Institute for Cancer Research and Prostate Cancer Canada, that will use MRI to help to better diagnose prostate cancer without invasive biopsy.

Continue reading – Making prostate cancer diagnosis more PRECISE

May 18, 2016

OICR congratulates J. Mark Lievonen and Laurence Klotz on their investiture in the Order of Canada

Mr. J. Mark Lievonen, a member of OICR’s Board of Directors, and Dr. Laurence Klotz, a doctor and researcher based at Sunnybrook Health Sciences Centre and the University of Toronto, who has conducted OICR-funded research into prostate cancer, were invested as Members in the Order of Canada at a ceremony in Ottawa on May 13.

Continue reading – OICR congratulates J. Mark Lievonen and Laurence Klotz on their investiture in the Order of Canada

May 1, 2016

OICR invests in early-stage Ontario oncology drug development

OICR is supporting new early stage drug discovery research in Ontario, with a $1.2 million investment from OICR’s Drug Discovery Program into five promising oncology research projects selected through a province-wide call for proposals.

This was a new approach to selecting projects for the Drug Discovery team’s research pipeline and one that aligns well with the strategic direction of the team and the Institute, says Dr. Rima Al-awar, Director of OICR’s Drug Discovery Program.

“Traditionally we have relied on several means to generate interest from the community, including informal outreach to other institutions and word of mouth says Al-awar. She points to the recent success of BCL6, a drug target that OICR’s Drug Discovery team developed from early stage research by Dr. Gil Privé at University Health Network. Collaborating with Privé, the team brought the BCL6 project to the point where it attracted major investment from industry.

Continue reading – OICR invests in early-stage Ontario oncology drug development

April 29, 2016

Technology developed with OICR funding receives $4 million in support from NCI

Pathcore slide and logoIn 2006 Dr. Martin Yaffe’s lab at Sunnybrook Research Institute developed a new way of preparing whole-mount sections of breast tissue, which opened up the exciting possibility of correlating pathology directly with medical imaging. However, the huge images that were produced posed a significant challenge to researchers; existing software for viewing images was either incapable of handling the large multi-scale images or it was too expensive and inflexible. To address these issues, Dr. Anne Martel, currently Chief Scientific Officer and co-founder of Pathcore, developed a new technology with funding assistance from OICR.

Continue reading – Technology developed with OICR funding receives $4 million in support from NCI

January 7, 2016

Ontario Institute for Cancer Research invests $1.2 million to support oncology drug development in Ontario

Five promising early stage research projects that would benefit from OICR’s input and expertise were selected from a province-wide call for proposals.

Toronto (January 7, 2016) – Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) announced today that OICR will invest $1.2 million in funding, plus expertise and in-kind support, to help bring five promising oncology drug development projects closer to the clinic.

Continue reading – Ontario Institute for Cancer Research invests $1.2 million to support oncology drug development in Ontario